Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Sermorelin

GHRH (1-29), GRF 1-29 NH2, Sermorelin acetate

Quick Stats
Studies 223
Trials 41
Score 4
1987 pubmed 6 citations

Effect of long-term administration of an analog of growth hormone-releasing factor on the GH response in rats.

Karashima. T T; Olsen. D D; Schally. A V AV

Key Findings

  • A single subcutaneous dose of the analog triggers a stronger and longer GH release than much larger doses of the natural hormone.
  • Repeated twice‑daily dosing for 4 weeks blunts the GH response, indicating tachyphylaxis.
  • Continuous low‑rate infusion for 7 days does not reduce the GH response, preserving sensitivity.

Practical Outcomes

  • For biohackers using sermorelin, avoid high‑frequency, high‑dose injection schedules that can lead to reduced effectiveness over time. Consider continuous low‑dose delivery (e.g., via a pump) or less frequent dosing to maintain a robust GH response.

Summary

In rats, a single injection of the sermorelin‑like peptide caused a big, lasting boost in growth hormone, but giving the same dose twice a day for weeks made the pituitary less responsive. A slow, continuous low‑dose infusion didn’t cause this drop, suggesting the way you dose matters for keeping the effect alive.

Abstract

The effect of the repeated or continuous administration of an analog of GH releasing factor (GH-RF), D-Tyr-1, D-Ala-2, Nle-27, GH-RF(1-29)-NH2 (DBO-29), on the subsequent response to this peptide was investigated in pentobarbital-anesthetized male rats. A sc administration of this analog induced a greater and more prolonged GH release than doses 10 times larger of GH-RF(1-29). The GH increase after sc injection of 10 micrograms/kg bw of the analog was greater than that induced by iv administration of 2 micrograms/kg bw of GH-RF(1-44). Pretreatment with 10 micrograms/kg bw of the analog did not affect the pituitary response to a strong stimulus (20 micrograms/kg bw) of GH-RF(1-44), 24 h later. Pretreatment with the analog in doses of 10 micrograms/kg bw, sc twice a day, 5 days per week for 4 weeks, significantly diminished the GH release in response to a sc injection of the analog (10 micrograms/kg bw), as compared to vehicle-pretreated controls (P less than 0.01). On the other hand, a continuous sc administration of 0.4 micrograms/h of the analog to intact rats for 7 days did not result in a decrease in GH response to a sc injection of the analog (10 micrograms/kg bw). Since the rats injected repeatedly with the analog for 4 weeks still showed a marked, although somewhat reduced response, analogs of this type may be useful clinically.

Study Information

Provider

pubmed

Year

1987

Date

1987-06-22T00:00:00.000Z

DOI

10.1016/0024-3205(87)90759-4

Citations

6

References

29